RNTX
Rein Therapeutics, Inc.
$0.99
+0.01 (+1.38%)
At close · Jul 2
Market Cap
$84.81M
Shares
85,539,032
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.99
Open$0.99
Day$0.97–1.02
52W$0.86–2.18
Avg vol 30d579K
Short int312K · 0.4% float · 1.0d
Short vol37%
Last earningsMay 15, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 15
Equibles Rating
blended score · not investment advice
Overall
Neutral
Technical · trend & momentum
Sell
◦
50 / 200-day cross
no cross
−
Price vs 200-day avg
−22% below
−
Price vs 50-day avg
−10% below
◦
RSI (14)
48 · neutral
+
MACD trend
positive
−
52-week position
10% · near low
Sentiment · smart money
Bullish
◦
Trend (MA cross)
50d $1 › 200d $1 — 200d above 50d
−
Institutional flow
-4% holders QoQ · +11 funds added
+
Insider flow
Net +$74.6K over 90 days · 0% sells
+
Short interest
0.37% of float · ▼ -19.4% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
46 holders — mid 3-yr range
Fundamentals
Strong
+
EPS growth
+44% Y/Y
−
Free cash flow
$-19.5M
+
Balance sheet
net cash $3.2M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
−22% below
Bearish
Price vs 50-day avg
−10% below
Bearish
RSI (14)
48 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
10% · near low
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +11 funds added
Insider flow
Accumulating
Net +$74.6K over 90 days · 0% sells
Short interest
Falling
0.37% of float · ▼ -19.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
46 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $1
Now $1 · 10%
52-wk high $2
vs 200-day avg -22%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RNTX
this stock
Rein Therapeutics, Inc.
|
$84.81M | -14.5% | — | — | 0.4% |
|
AKTX
Akari Therapeutics Plc
|
$953.21B | -9.9% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$470.30B | -2.0% | +22179.2% | 957.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.02B | +16.5% | +46.2% | 31.3 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.80B | -15.1% | +20.8% | 16.3 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RNTX | +6.0% | -2.8% | -18.7% | -4.7% | -14.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | +4.6% | -1.5% | -26.8% | -4.4% | -23.8% |